Pharmacogenetic approaches to the treatment of alcohol addiction (original) (raw)

• Rehm, J. et al. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet 373, 2223–2233 (2009).
  Article PubMed Google Scholar
• Nutt, D. J., King, L. A. & Phillips, L. D. Drug harms in the UK: a multicriteria decision analysis. Lancet 376, 1558–1565 (2010).
  Article PubMed Google Scholar
• Hasin, D. S., Stinson, F. S., Ogburn, E. & Grant, B. F. Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch. Gen. Psychiatry 64, 830–842 (2007).
  Article PubMed Google Scholar
• McLellan, A. T., Lewis, D. C., O'Brien, C. P. & Kleber, H. D. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA 284, 1689–1695 (2000).
  Article CAS PubMed Google Scholar
• Goldman, D., Oroszi, G. & Ducci, F. The genetics of addictions: uncovering the genes. Nature Rev. Genet. 6, 521–532 (2005).
  Article CAS PubMed Google Scholar
• Bouza, C., Angeles, M., Munoz, A. & Amate, J. M. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction 99, 811–828 (2004).
  Article PubMed Google Scholar
• Amato, L. et al. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J. Subst. Abuse Treat. 28, 321–329 (2005).
  Article PubMed Google Scholar
• Wu, P., Wilson, K., Dimoulas, P. & Mills, E. Effectiveness of smoking cessation therapies: a systematic review and meta-analysis. BMC Public Health 6, 300 (2006).
  Article PubMed PubMed Central Google Scholar
• Willenbring, M. L., Massey, S. H. & Gardner, M. B. Helping patients who drink too much: an evidence-based guide for primary care physicians. Am. Fam. Physician 80, 44–50 (2009).
  PubMed Google Scholar
• Mark, T. L., Kranzler, H. R. & Song, X. Understanding US addiction physicians' low rate of naltrexone prescription. Drug Alcohol Depend. 71, 219–228 (2003).
  Article PubMed Google Scholar
• American Psychiatric Association. Diagnostics and Statistical Manual of Mental Disorders 4th edn (American Psychiatric Press, Washington, District of Columbia, 2000).
• Cloninger, C. R. Neurogenetic adaptive mechanisms in alcoholism. Science 236, 410–416 (1987).
  Article CAS PubMed Google Scholar
• Vaillant, G. E. A long-term follow-up of male alcohol abuse. Arch. Gen. Psychiatry 53, 243–249 (1996).
  Article CAS PubMed Google Scholar
• Vaillant, G. E. The Natural History of Alcoholism: Causes, Patterns, and Paths to Recovery (Harvard Univ. Press, Cambridge, USA, 1983).
  Google Scholar
• Fein, G. & Landman, B. Treated and treatment-naive alcoholics come from different populations. Alcohol 36, 19–26 (2005).
  Article PubMed PubMed Central Google Scholar
• Kendler, K. S., Thornton, L. M. & Gardner, C. O. Genetic risk, number of previous depressive episodes, and stressful life events in predicting onset of major depression. Am. J. Psychiatry 158, 582–586 (2001).
  Article CAS PubMed Google Scholar
• Ballenger, J. C. & Post, R. M. Kindling as a model for alcohol withdrawal syndromes. Br. J. Psychiatry 133, 1–14 (1978).
  Article CAS PubMed Google Scholar
• Heilig, M. & Koob, G. F. A key role for corticotropin-releasing factor in alcohol dependence. Trends Neurosci. 30, 399–406 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Heilig, M. & Egli, M. Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms. Pharmacol. Ther. 111, 855–876 (2006).
  Article CAS PubMed Google Scholar
• Koob, G. F. & Volkow, N. D. Neurocircuitry of addiction. Neuropsychopharmacology 35, 217–238 (2010).
  Article PubMed Google Scholar
• Heinz, A. et al. Reward craving and withdrawal relief craving: assessment of different motivational pathways to alcohol intake. Alcohol Alcohol. 38, 35–39 (2003).
  Article PubMed Google Scholar
• Robinson, T. E. & Berridge, K. C. Addiction. Annu. Rev. Psychol. 54, 25–53 (2003).
  Article PubMed Google Scholar
• Wise, R. A. Dopamine, learning and motivation. Nature Rev. Neurosci. 5, 483–494 (2004).
  Article CAS Google Scholar
• Di Chiara, G. et al. Dopamine and drug addiction: the nucleus accumbens shell connection. Neuropharmacology 47, 227–241 (2004).
  Article CAS PubMed Google Scholar
• Di Chiara, G. & Imperato, A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc. Natl Acad. Sci. USA 85, 5274–5278 (1988).
  Article CAS PubMed PubMed Central Google Scholar
• Spanagel, R. Alcoholism: a systems approach from molecular physiology to addictive behavior. Physiol. Rev. 89, 649–705 (2009).
  Article CAS PubMed Google Scholar
• Boileau, I. et al. Alcohol promotes dopamine release in the human nucleus accumbens. Synapse 49, 226–231 (2003).
  Article CAS PubMed Google Scholar
• Gilman, J. M., Ramchandani, V. A., Davis, M. B., Bjork, J. M. & Hommer, D. W. Why we like to drink: a functional magnetic resonance imaging study of the rewarding and anxiolytic effects of alcohol. J. Neurosci. 28, 4583–4591 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Spanagel, R., Herz, A. & Shippenberg, T. S. Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. Proc. Natl Acad. Sci. USA 89, 2046–2050 (1992).
  Article CAS PubMed PubMed Central Google Scholar
• Johnson, S. W. & North, R. A. Opioids excite dopamine neurons by hyperpolarization of local interneurons. J. Neurosci. 12, 483–488 (1992).
  Article CAS PubMed PubMed Central Google Scholar
• Tanda, G. L. & Di Chiara, G. A dopamine-μ1 opioid link in the rat ventral tegmentum shared by palatable food (Fonzies) and non-psychostimulant drugs of abuse. Eur. J. Neurosci. 10, 1179–1187 (1998).
  Article CAS PubMed Google Scholar
• Rubio, G. et al. Clinical predictors of response to naltrexone in alcoholic patients: who benefits most from treatment with naltrexone? Alcohol Alcohol. 40, 227–233 (2005).
  Article CAS PubMed Google Scholar
• King, A. C., Volpicelli, J. R., Frazer, A. & O'Brien, C. P. Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence. Psychopharmacology 129, 15–22 (1997).
  Article CAS PubMed Google Scholar
• Krishnan-Sarin, S., Krystal, J. H., Shi, J., Pittman, B. & O'Malley, S. S. Family history of alcoholism influences naltrexone-induced reduction in alcohol drinking. Biol. Psychiatry 62, 694–697 (2007).
  Article CAS PubMed Google Scholar
• Bergen, A. W. et al. Mu opioid receptor gene variants: lack of association with alcohol dependence. Mol. Psychiatry 2, 490–494 (1997).
  Article CAS PubMed Google Scholar
• Bond, C. et al. Single-nucleotide polymorphism in the human mu opioid receptor gene alters β-endorphin binding and activity: possible implications for opiate addiction. Proc. Natl Acad. Sci. USA 95, 9608–9613 (1998). This paper identified the functional N40D variation in the MOR (the target for naltrexone).
  Article CAS PubMed PubMed Central Google Scholar
• Bart, G. et al. Increased attributable risk related to a functional mu-opioid receptor gene polymorphism in association with alcohol dependence in central Sweden. Neuropsychopharmacology 30, 417–422 (2005).
  Article CAS PubMed Google Scholar
• Bart, G. et al. Substantial attributable risk related to a functional mu-opioid receptor gene polymorphism in association with heroin addiction in central Sweden. Mol. Psychiatry 9, 547–549 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Kroslak, T. The single nucleotide polymorphism A118G alters functional properties of the human mu opioid receptor. J. Neurochem. 103, 177–187 (2007).
  Google Scholar
• Zhang, Y., Wang, D. X., Johnson, A. D., Papp, A. C. & Sadee, W. Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. J. Biol. Chem. 280, 32618–32624 (2005).
  Article CAS PubMed Google Scholar
• Arias, A., Feinn, R. & Kranzler, H. R. Association of an Asn40Asp (A118G) polymorphism in the μ-opioid receptor gene with substance dependence: a meta-analysis. Drug Alcohol Depend. 83, 262–268 (2006).
  Article CAS PubMed Google Scholar
• Oslin, D. W. et al. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 28, 1546–1552 (2003). This paper was the first to propose that therapeutic efficacy of naltrexone might be restricted to carriers of the OPRM1 118G allele.
  Article CAS PubMed Google Scholar
• Anton, R. F. et al. An evaluation of μ-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch. Gen. Psychiatry 65, 135–144 (2008). This paper provided an independent clinical replication of the finding that naltrexone is primarily effective in carriers of the OPRM1 118G allele.
  Article CAS PubMed PubMed Central Google Scholar
• Gelernter, J. et al. Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA cooperative study. Alcohol. Clin. Exp. Res. 31, 555–563 (2007).
  CAS PubMed Google Scholar
• Ray, L. A. & Hutchison, K. E. Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response — a double-blind placebo-controlled study. Arch. Gen. Psychiatry 64, 1069–1077 (2007).
  Article CAS PubMed Google Scholar
• Ray, L. A. & Hutchison, K. E. A polymorphism of the mu-opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans. Alcohol. Clin. Exp. Res. 28, 1789–1795 (2004).
  Article CAS PubMed Google Scholar
• Barr, C. S. & Goldman, D. Non-human primate models of inheritance vulnerability to alcohol use disorders. Addict. Biol. 11, 374–385 (2006).
  Article PubMed Google Scholar
• Miller, G. M. et al. A mu-opioid receptor single nucleotide polymorphism in rhesus monkey: association with stress response and aggression. Mol. Psychiatry 9, 99–108 (2004).
  Article CAS PubMed Google Scholar
• Barr, C. S. et al. Association of a functional polymorphism in the mu-opioid receptor gene with alcohol response and consumption in male rhesus macaques. Arch. Gen. Psychiatry 64, 369–376 (2007). A demonstration that the psychomotor response to alcohol and alcohol preference are markedly enhanced in rhesus macaques that carry an OPRM1 77G allele that is functionally equivalent to the human 118G allele, pointing to the possibility that mesolimbic dopamine circuitry is preferentially activated by alcohol in these subjects.
  Article CAS PubMed Google Scholar
• Barr, C. S. et al. Suppression of alcohol preference by naltrexone in the rhesus macaque: a critical role of genetic variation at the μ-opioid receptor gene locus. Biol. Psychiatry 67, 78–80 (2010). This study demonstrated in a closely controlled experimental system that alcohol preference is selectively suppressed by naltrexone in rhesus carriers of the OPRM1 77G allele.
  Article CAS PubMed PubMed Central Google Scholar
• Vallender, E. J., Ruedi-Bettschen, D., Miller, G. M. & Platt, D. M. A pharmacogenetic model of naltrexone-induced attenuation of alcohol consumption in rhesus monkeys. Drug Alcohol Depend. 109, 252–256 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Zhang, H. P. et al. Association between two mu-opioid receptor gene (OPRM1) haplotype blocks and drug or alcohol dependence. Hum. Mol. Genet. 15, 807–819 (2006).
  Article CAS PubMed Google Scholar
• Oroszi, G. et al. OPRM1 Asn40Asp predicts response to naltrexone treatment: a haplotype-based approach. Alcohol. Clin. Exp. Res. 33, 383–393 (2009).
  Article CAS PubMed Google Scholar
• Shabalina, S. A. et al. Expansion of the human mu-opioid receptor gene architecture: novel functional variants. Hum. Mol. Genet. 18, 1037–1051 (2009).
  Article CAS PubMed Google Scholar
• Ramchandani, V. A. et al. A genetic determinant of the striatal dopamine response to alcohol in men. Mol. Psychiatry 16, 809–817 (2011). This study showed that, as predicted by reference 49, alcohol-induced mesolimbic dopamine-release measured using PET is markedly greater in social drinkers carrying the OPRM1 118G allele than in those homozygous for the major 118A allele. It also showed that insertion of the 118G SNP into a humanized mouse is sufficient to confer increased mesolimbic dopamine release in response to alcohol, as measured directly by microdialysis.
  Article CAS PubMed Google Scholar
• Mague, S. D. et al. Mouse model of OPRM1 (A118G) polymorphism has sex-specific effects on drug-mediated behavior. Proc. Natl Acad. Sci. USA 106, 10847–10852 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Mahmoud, S. et al. Pharmacological consequence of the A118G μ opioid receptor polymorphism on morphine- and fentanyl-mediated modulation of Ca2+ channels in humanized mouse sensory neurons. Anesthesiology 14 Sep 2011 (doi:10.1097/ALN.0b013e318231fc11).
  Article CAS PubMed Google Scholar
• Lotsch, J. & Geisslinger, G. Relevance of frequent mu-opioid receptor polymorphisms for opioid activity in healthy volunteers. Pharmacogenomics J. 6, 200–210 (2006).
  Article CAS PubMed Google Scholar
• Pang, G. S. Y., Wang, J. B., Wang, Z. H., Goh, C. & Lee, C. G. L. The G allele of SNP E1/A118G at the mu-opioid receptor gene locus shows genomic evidence of recent positive selection. Pharmacogenomics 10, 1101–1109 (2009).
  Article CAS PubMed Google Scholar
• Wand, G. S., Mangold, D., El Deiry, S., McCaul, M. E. & Hoover, D. Family history of alcoholism and hypothalamic opioidergic activity. Arch. Gen. Psychiatry 55, 1114–1119 (1998).
  Article CAS PubMed Google Scholar
• Wand, G. S. et al. The mu-opioid receptor gene polymorphism (A118G) alters HPA axis activation induced by opioid receptor blockade. Neuropsychopharmacology 26, 106–114 (2002).
  Article CAS PubMed Google Scholar
• Hernandez-Avila, C. A. et al. Population-specific effects of the Asn40Asp polymorphism at the mu-opioid receptor gene (OPRM1) on HPA-axis activation. Pharmacogenet. Genomics 17, 1031–1038 (2007).
  Article CAS PubMed Google Scholar
• Kiefer, F., Jahn, H., Otte, C., Naber, D. & Wiedemann, K. Hypothalamic-pituitary-adrenocortical axis activity: a target of pharmacological anticraving treatment? Biol. Psychiatry 60, 74–76 (2006).
  Article CAS PubMed Google Scholar
• Kim, S.-G. et al. A mu opioid receptor gene polymorphism (A118G) and naltrexone treatment response in adherent Korean alcohol-dependent patients. Psychopharmacology 201, 611–618 (2009).
  Article CAS PubMed Google Scholar
• Heilig, M., Egli, M., Crabbe, J. C. & Becker, H. C. Acute withdrawal, protracted abstinence and negative affect in alcoholism: are they linked? Addict. Biol. 15, 169–184 (2010).
  Article PubMed PubMed Central Google Scholar
• Solomon, R. L. & Corbit, J. D. An opponent-process theory of motivation. I. Temporal dynamics of affect. Psychol. Rev. 81, 119–145 (1974).
  Article CAS PubMed Google Scholar
• Koob, G. F., Vaccarino, F., Amalric, M. & Bloom, F. E. Brain Reward Systems and Abuse (eds Engel, J. & Oreland, L.) 35–50 (Raven Press, New York, 1987).
  Google Scholar
• Koob, G. F. & Le Moal, M. Addiction and the brain antireward system. Annu. Rev. Psychol. 59, 29–53 (2008).
  Article PubMed Google Scholar
• Koob, G. F. & Le Moal, M. Plasticity of reward neurocircuitry and the 'dark side' of drug addiction. Nature Neurosci. 8, 1442–1444 (2005).
  Article CAS PubMed Google Scholar
• Vale, W., Spiess, J., Rivier, C. & Rivier, J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and β-endorphin. Science 213, 1394–1397 (1981).
  Article CAS PubMed Google Scholar
• Swanson, L. W., Sawchenko, P. E., Rivier, J. & Vale, W. W. Organization of ovine corticotropin-releasing factor immunoreactive cells and fibers in the rat brain: an immunohistochemical study. Neuroendocrinology 36, 165–186 (1983).
  Article CAS PubMed Google Scholar
• Heinrichs, S. C. & Koob, G. F. Corticotropin-releasing factor in brain: a role in activation, arousal, and affect regulation. J. Pharmacol. Exp. Ther. 311, 427–440 (2004).
  Article CAS PubMed Google Scholar
• Muller, M. B. & Wurst, W. Getting closer to affective disorders: the role of CRH receptor systems. Trends Mol. Med. 10, 409–415 (2004).
  Article CAS PubMed Google Scholar
• Griebel, G. et al. 4-(2-Chloro-4-methoxy-5-methylphenyl)-_N_-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-_N_-(2-propynyl)-1,3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor1 receptor antagonist. II. Characterization in rodent models of stress-related disorders. J. Pharmacol. Exp. Ther. 301, 333–345 (2002).
  Article CAS PubMed Google Scholar
• Gully, D. et al. 4-(2-Chloro-4-methoxy-5-methylphenyl)-_N_-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-_N_-(2-propynyl)-1,3-thiazol-2-amine hydrochloride (SSR125543A): a potent and selective corticotrophin-releasing factor1 receptor antagonist. I. Biochemical and pharmacological characterization. J. Pharmacol. Exp. Ther. 301, 322–332 (2002).
  Article CAS PubMed Google Scholar
• Hokfelt, T., Johansson, O. & Goldstein, M. Chemical anatomy of the brain. Science 225, 1326–1334 (1984).
  Article CAS PubMed Google Scholar
• Gehlert, D. R. et al. 3-(4-Chloro-2-morpholin-4-yl-thiazol-5-yl)-8-(1-ethylpropyl)-2,6-dimethyl- imidazo[1,2-_b_]pyridazine: a novel brain-penetrant, orally available corticotropin-releasing factor receptor 1 antagonist with efficacy in animal models of alcoholism. J. Neurosci. 27, 2718–2726 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Baldwin, H. A., Rassnick, S., Rivier, J., Koob, G. F. & Britton, T. K. CRF antagonist reverses the “anxiogenic” response to ethanol withdrawal in the rat. Psychopharmacology 103, 227–232 (1991).
  Article CAS PubMed Google Scholar
• Rassnick, S., Heinrichs, S. C., Britton, K. T. & Koob, G. F. Microinjection of a corticotropin-releasing factor antagonist into the central nucleus of the amygdala reverses anxiogenic-like effects of ethanol withdrawal. Brain Res. 605, 25–32 (1993).
  Article CAS PubMed Google Scholar
• Merlo, P. E. et al. Increase of extracellular corticotropin-releasing factor-like immunoreactivity levels in the amygdala of awake rats during restraint stress and ethanol withdrawal as measured by microdialysis. J. Neurosci. 15, 5439–5447 (1995).
  Article Google Scholar
• Valdez, G. R., Zorrilla, E. P., Roberts, A. J. & Koob, G. F. Antagonism of corticotropin-releasing factor attenuates the enhanced responsiveness to stress observed during protracted ethanol abstinence. Alcohol 29, 55–60 (2003).
  Article CAS PubMed Google Scholar
• Sommer, W. H. et al. Upregulation of voluntary alcohol intake, behavioral sensitivity to stress, and amygdala Crhr1 expression following a history of dependence. Biol. Psychiatry 63, 139–145 (2008).
  Article PubMed Google Scholar
• Overstreet, D. H., Knapp, D. J. & Breese, G. R. Accentuated decrease in social interaction in rats subjected to repeated ethanol withdrawals. Alcohol. Clin. Exp. Res. 26, 1259–1268 (2002).
  Article PubMed PubMed Central Google Scholar
• Knapp, D. J., Overstreet, D. H., Moy, S. S. & Breese, G. R. SB242084, flumazenil, and CRA1000 block ethanol withdrawal-induced anxiety in rats. Alcohol 32, 101–111 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Overstreet, D. H., Knapp, D. J. & Breese, G. R. Modulation of multiple ethanol withdrawal-induced anxiety-like behavior by CRF and CRF1 receptors. Pharmacol. Biochem. Behav. 77, 405–413 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Breese, G. R., Overstreet, D. H., Knapp, D. J. & Navarro, M. Prior multiple ethanol withdrawals enhance stress-induced anxiety-like behavior: inhibition by CRF1- and benzodiazepine-receptor antagonists and a 5-HT1a-receptor agonist. Neuropsychopharmacology 30, 1662–1669 (2005).
  Article CAS PubMed Google Scholar
• Gilman, J. M. & Hommer, D. W. Modulation of brain response to emotional images by alcohol cues in alcohol-dependent patients. Addict. Biol. 13, 423–434 (2008).
  Article PubMed Google Scholar
• Breese, G. R., Overstreet, D. H. & Knapp, D. J. Conceptual framework for the etiology of alcoholism: a “kindling”/stress hypothesis. Psychopharmacology 178, 367–380 (2005).
  Article CAS PubMed Google Scholar
• Epstein, D. H., Preston, K. L., Stewart, J. & Shaham, Y. Toward a model of drug relapse: an assessment of the validity of the reinstatement procedure. Psychopharmacology 189, 1–16 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Le, A. & Shaham, Y. Neurobiology of relapse to alcohol in rats. Pharmacol. Ther. 94, 137–156 (2002).
  Article CAS PubMed Google Scholar
• Le, A. D. et al. The role of corticotrophin-releasing factor in stress-induced relapse to alcohol-seeking behavior in rats. Psychopharmacology 150, 317–324 (2000).
  Article CAS PubMed Google Scholar
• Liu, X. & Weiss, F. Additive effect of stress and drug cues on reinstatement of ethanol seeking: exacerbation by history of dependence and role of concurrent activation of corticotropin-releasing factor and opioid mechanisms. J. Neurosci. 22, 7856–7861 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Hansson, A. C. et al. Variation at the rat Crhr1 locus and sensitivity to relapse into alcohol seeking induced by environmental stress. Proc. Natl Acad. Sci. USA 103, 15236–15241 (2006). Using a genetically selected alcohol preferring rat line, the authors demonstrated for the first time that genetic variation affecting the CRF system influences stress-induced relapse to alcohol seeking and escalation of alcohol consumption. They showed that the potency of a CRF 1 antagonist was enhanced in animals with innate overexpression of CRF 1.
  Article CAS PubMed PubMed Central Google Scholar
• Kalivas, P. W. & McFarland, K. Brain circuitry and the reinstatement of cocaine-seeking behavior. Psychopharmacology 168, 44–56 (2003).
  Article CAS PubMed Google Scholar
• Le, A. D., Harding, S., Juzytsch, W., Fletcher, P. J. & Shaham, Y. The role of corticotropin-releasing factor in the median raphe nucleus in relapse to alcohol. J. Neurosci. 22, 7844–7849 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Vertes, R. P., Fortin, W. J. & Crane, A. M. Projections of the median raphe nucleus in the rat. J. Comp. Neurol. 407, 555–582 (1999).
  Article CAS PubMed Google Scholar
• Le, A. D. et al. Effects of naltrexone and fluoxetine on alcohol self-administration and reinstatement of alcohol seeking induced by priming injections of alcohol and exposure to stress. Neuropsychopharmacology 21, 435–444 (1999).
  Article CAS PubMed Google Scholar
• Marinelli, P. W. et al. The CRF1 receptor antagonist antalarmin attenuates yohimbine-induced increases in operant alcohol self-administration and reinstatement of alcohol seeking in rats. Psychopharmacology 195, 345–355 (2007).
  Article CAS PubMed Google Scholar
• Funk, C. K., Zorrilla, E. P., Lee, M. J., Rice, K. C. & Koob, G. F. Corticotropin-releasing factor 1 antagonists selectively reduce ethanol self-administration in ethanol-dependent rats. Biol. Psychiatry 61, 78–86 (2007).
  Article CAS PubMed Google Scholar
• Funk, C. K., O'Dell, L. E., Crawford, E. F. & Koob, G. F. Corticotropin-releasing factor within the central nucleus of the amygdala mediates enhanced ethanol self-administration in withdrawn, ethanol-dependent rats. J. Neurosci. 26, 11324–11332 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Sparta, D. R. et al. Blockade of the corticotropin releasing factor type 1 receptor attenuates elevated ethanol drinking associated with drinking in the dark procedures. Alcohol. Clin. Exp. Res. 32, 259–265 (2008).
  Article CAS PubMed Google Scholar
• Lowery, E. G. et al. CRF-1 antagonist and CRF-2 agonist decrease binge-like ethanol drinking in C57BL/56J mice independent of the HPA axis. Neuropsychopharmacology 35, 1241–1252 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Hansson, A. C., Cippitelli, A., Sommer, W., Ciccocioppo, R. & Heilig, M. Region-specific down regulation of Crhr1 gene expression in alcohol preferring msP rats following ad lib access to alcohol. Addict. Biol. 12, 30–34 (2007).
  Article CAS PubMed Google Scholar
• Makino, S., Hashimoto, K. & Gold, P. W. Multiple feedback mechanisms activating corticotropin-releasing hormone system in the brain during stress. Pharmacol. Biochem. Behav. 73, 147–158 (2002).
  Article CAS PubMed Google Scholar
• Barr, C. S. et al. Functional CRH variation increases stress-induced alcohol consumption in primates. Proc. Natl Acad. Sci. USA 106, 14593–14598 (2009). This study demonstrated a gene × environment interaction, such that variation at the rhesus CRF gene locus that moderates sensitivity to feedback inhibition by cortisol moderated alcohol preference in adult life if the animals had been reared under conditions of early life adversity, but not otherwise.
  Article CAS PubMed PubMed Central Google Scholar
• Treutlein, J. et al. Genetic association of the human corticotropin releasing hormone receptor 1 (CRHR1) with binge drinking and alcohol intake patterns in two independent samples. Mol. Psychiatry 11, 594–602 (2006). The first indication that genetic variation affecting the CRF system is associated with alcohol-use phenotypes in humans.
  Article CAS PubMed Google Scholar
• Blomeyer, D. et al. Interaction between CRHR1 gene and stressful life events predicts adolescent heavy alcohol use. Biol. Psychiatry 63, 146–151 (2008). This study provided data supporting the notion that genetic variation at the CRFR1 locus and exposure to life stressors interact to determine alcohol use phenotypes in humans.
  Article CAS PubMed Google Scholar
• Nelson, E. C. et al. H2 haplotype at chromosome 17q21.31 protects against childhood sexual abuse-associated risk for alcohol consumption and dependence. Addict. Biology 15, 1–11 (2010).
  Article CAS Google Scholar
• Kendler, K. S. et al. Childhood sexual abuse and adult psychiatric and substance use disorders in women: an epidemiological and cotwin control analysis. Arch. Gen. Psychiatry 57, 953–959 (2000).
  Article CAS PubMed Google Scholar
• Sinha, R., Shaham, Y. & Heilig, M. Translational and reverse translational research on the role of stress in drug craving and relapse. Psychopharmacology 15 Apr 2011 (doi: 10.1007/s00213-011-2263-y).
  Article CAS PubMed PubMed Central Google Scholar
• Zobel, A. W. et al. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J. Psychiatr. Res. 34, 171–181 (2000).
  Article CAS PubMed Google Scholar
• Binneman, B. et al. A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression. Am. J. Psychiatry 165, 617–620 (2008).
  Article PubMed Google Scholar
• Coric, V. et al. Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder. Depress. Anxiety 27, 417–425 (2010).
  Article CAS PubMed Google Scholar
• Binder, E. B. et al. Association of FKBP5 polymorphisms and childhood abuse with risk of posttraumatic stress disorder symptoms in adults. JAMA 299, 1291–1305 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Heilig, M., Koob, G. F., Ekman, R. & Britton, K. T. Corticotropin-releasing factor and neuropeptide Y: role in emotional integration. Trends Neurosci. 17, 80–85 (1994).
  Article CAS PubMed Google Scholar
• Zhou, Z. et al. Genetic variation in human NPY expression affects stress response and emotion. Nature 452, 997–1001 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Sommer, W. H. et al. Human NPY promoter variation rs16147:T>C as a moderator of prefrontal NPY gene expression and negative affect. Hum. Mutat. 31, e1594–e1608 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Caspi, A. et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 301, 386–389 (2003).
  Article CAS PubMed Google Scholar
• Zubieta, J. K. et al. COMT val 158 met genotype affects μ-opioid neurotransmitter responses to a pain stressor. Science 299, 1240–1243 (2003).
  Article CAS PubMed Google Scholar
• Risch, N. et al. Interaction between the serotonin transporter gene (5-HTTLPR), stressful life events, and risk of depression: a meta-analysis. JAMA 301, 2462–2471 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Caspi, A., Hariri, A. R., Holmes, A., Uher, R. & Moffitt, T. E. Genetic sensitivity to the environment: the case of the serotonin transporter gene and its implications for studying complex diseases and traits. Am. J. Psychiatry 167, 509–527 (2010).
  Article PubMed PubMed Central Google Scholar
• Long, J. C. et al. Evidence for genetic linkage to alcohol dependence on chromosomes 4 and 11 from an autosome-wide scan in an American Indian population. Am. J. Med. Genet. 81, 216–221 (1998).
  Article CAS PubMed Google Scholar
• Edenberg, H. J. et al. Variations in GABRA2, encoding the α 2 subunit of the GABAA receptor, are associated with alcohol dependence and with brain oscillations. Am. J. Hum. Genet. 74, 705–714 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Porjesz, B. et al. Linkage disequilibrium between the β frequency of the human EEG and a GABAA receptor gene locus. Proc. Natl Acad. Sci. USA 99, 3729–3733 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Lappalainen, J. et al. Association between alcoholism and γ-amino butyric acid α2 receptor subtype in a Russian population. Alcohol. Clin. Exp. Res. 29, 493–498 (2005).
  Article CAS PubMed Google Scholar
• Covault, J., Gelernter, J., Hesselbrock, V., Nellissery, M. & Kranzler, H. R. Allelic and haplotypic association of GABRA2 with alcohol dependence. Am. J. Med Genet. B Neuropsychiatr. Genet. 129B, 104–109 (2004).
  Article PubMed Google Scholar
• Fehr, C. et al. Confirmation of association of the GABRA2 gene with alcohol dependence by subtype-specific analysis. Psychiatr. Genet. 16, 9–17 (2006).
  Article PubMed Google Scholar
• Morrow, A. L., VanDoren, M. J., Penland, S. N. & Matthews, D. B. The role of GABAergic neuroactive steroids in ethanol action, tolerance and dependence. Brain Res. Brain Res. Rev. 37, 98–109 (2001).
  Article CAS PubMed Google Scholar
• Pierucci-Lagha, A. et al. GABRA2 alleles moderate the subjective effects of alcohol, which are attenuated by finasteride. Neuropsychopharmacology 30, 1193–1203 (2005).
  Article CAS PubMed Google Scholar
• Roh, S. et al. Role of GABRA2 in moderating subjective responses to alcohol. Alcohol. Clin. Exp. Res. 35, 400–407 (2011).
  Article CAS PubMed Google Scholar
• Villafuerte, S. et al. Impulsiveness and insula activation during reward anticipation are associated with genetic variants in GABRA2 in a family sample enriched for alcoholism. Mol. Psychiatry 12 Apr 2011 (doi: 10.1038/mp.2011.33).
  Article CAS PubMed PubMed Central Google Scholar
• Knutson, B., Fong, G. W., Bennett, S. M., Adams, C. M. & Hommer, D. A region of mesial prefrontal cortex tracks monetarily rewarding outcomes: characterization with rapid event-related fMRI. Neuroimage 18, 263–272 (2003).
  Article PubMed Google Scholar
• Knutson, B., Adams, C. M., Fong, G. W. & Hommer, D. Anticipation of increasing monetary reward selectively recruits nucleus accumbens. J. Neurosci. 21, RC159 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Torrens, M., Fonseca, F., Mateu, G. & Farre, M. Efficacy of antidepressants in substance use disorders with and without comorbid depression. A systematic review and meta-analysis. Drug Alcohol Depend. 78, 1–22 (2005).
  Article CAS PubMed Google Scholar
• Johnson, B. A., Ait-Daoud, N., Ma, J. Z. & Wang, Y. Ondansetron reduces mood disturbance among biologically predisposed, alcohol-dependent individuals. Alcohol. Clin. Exp. Res. 27, 1773–1779 (2003).
  Article CAS PubMed Google Scholar
• Johnson, B. A., Roache, J. D., Ait-Daoud, N., Zanca, N. A. & Velazquez, M. Ondansetron reduces the craving of biologically predisposed alcoholics. Psychopharmacology 160, 408–413 (2002).
  Article CAS PubMed Google Scholar
• Johnson, B. A. et al. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients - a randomized controlled trial. JAMA 284, 963–971 (2000).
  Article CAS PubMed Google Scholar
• Dremencov, E., Weizmann, Y., Kinor, N., Gispan-Herman, I. & Yadid, G. Modulation of dopamine transmission by 5HT2C and 5HT3 receptors: a role in the antidepressant response. Curr. Drug Targets 7, 165–175 (2006).
  Article CAS PubMed Google Scholar
• Lesch, K. P. et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274, 1527–1531 (1996).
  Article CAS PubMed Google Scholar
• Johnson, B. A. et al. Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking. Am. J. Psychiatry 168, 265–275 (2011).
  Article PubMed PubMed Central Google Scholar
• Kenna, G. A. et al. A within group design of nontreatment seeking 5-HTTLPR genotyped alcohol dependent subjects receiving ondansetron and sertraline. Alcohol. Clin. Exp. Res. 33, 315–323 (2009).
  Article CAS PubMed Google Scholar
• Seneviratne, C., Huang, W., Ait-Daoud, N., Li, M. D. & Johnson, B. A. Characterization of a functional polymorphism in the 3′ UTR of SLC6A4 and its association with drinking intensity. Alcohol. Clin. Exp. Res. 33, 332–339 (2009).
  Article CAS PubMed Google Scholar
• Miller, G. Is pharma running out of brainy ideas? Science 329, 502–504 (2010).
  Article CAS PubMed Google Scholar
• Koob, G. F., Lloyd, G. K. & Mason, B. J. Development of pharmacotherapies for drug addiction: a Rosetta Stone approach. Nature Rev. Drug Discov. 8, 500–515 (2009).
  Article CAS Google Scholar
• Johnson, B. A., Ait-Daoud, N., Akhtar, F. Z. & Ma, J. Z. Oral topiramate reduces the consequences of drinking and improves the quality of life of alcohol-dependent individuals: a randomized controlled trial. Arch. Gen. Psychiatry 61, 905–912 (2004).
  Article CAS PubMed Google Scholar
• Akil, H. et al. Endogenous opioids — biology and function. Annu. Rev. Neurosci. 7, 223–255 (1984).
  Article CAS PubMed Google Scholar
• Snyder, S. H. & Pasternak, G. W. Historical review: opioid receptors. Trends Pharmacol. Sci. 24, 198–205 (2003).
  Article CAS PubMed Google Scholar
• Altshuler, H. L., Phillips, P. E. & Feinhandler, D. A. Alteration of ethanol self-administration by naltrexone. Life Sci. 26, 679–688 (1980).
  Article CAS PubMed Google Scholar
• Egli, M. Can. experimental paradigms and animal models be used to discover clinically effective medications for alcoholism? Addict. Biology 10, 309–319 (2005).
  Article CAS Google Scholar
• Volpicelli, J. R., Alterman, A. I., Hayashida, M. & O'Brien, C. P. Naltrexone in the treatment of alcohol dependence. Arch. Gen. Psychiatry 49, 876–880 (1992).
  Article CAS PubMed Google Scholar
• Hunt, W. A., Barnett, L. W. & Branch, L. G. Relapse rates in addiction programs. J. Clin. Psychol. 27, 455–456 (1971).
  Article CAS PubMed Google Scholar
• O'Malley, S. S. et al. Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch. Gen. Psychiatry 49, 881–887 (1992).
  Article CAS PubMed Google Scholar
• Monterosso, J. R. et al. Predicting treatment response to naltrexone: the influence of craving and family history. Am. J. Addict. 10, 258–268 (2001).
  Article CAS PubMed Google Scholar
• Gianoulakis, C. et al. Different pituitary β-endorphin and adrenal cortisol response to ethanol in individuals with high and low risk for future development of alcoholism. Life Sci. 45, 1097–1109 (1989).
  Article CAS PubMed Google Scholar
• Waldhoer, M., Bartlett, S. E. & Whistler, J. L. Opioid receptors. Annu. Rev. Biochem. 73, 953–990 (2004).
  Article CAS PubMed Google Scholar
• Di Chiara, G., Acquas, E. & Tanda, G. Ethanol as a neurochemical surrogate of conventional reinforcers: the dopamine-opioid link. Alcohol 13, 13–17 (1996).
  Article CAS PubMed Google Scholar
• Paxinos, G. & Watson, C. The Rat Brain in Stereotaxic Coordinates (Elsevier Academic Press, Amsterdam, 2005).
  Google Scholar